Leerink Partners Downgrades Merus N.V. (MRUS) to Market Perform

Leerink Partners analyst Andrew Berens downgraded Merus N.V. (NASDAQ: MRUS) from Outperform to Market Perform with a price target of $97.00 (from $95.00).

The analyst comments: "On Monday morning, MRUS and GMAB announced plans for GMAB to acquire MRUS in a transaction worth ~$8bn, representing a ~40% premium (see note). Given the pending transaction, the stock is no longer trading on fundamentals but rather on news flow regarding the details of the pending transaction. Our previous price target was $95/share, which did not include the CRC opportunity, with data expected by year-end, potentially at a medical conference, and guidance re-affirmed by MRUS management this week. We also think it is likely that GMAB was given access to the data as part of the diligence process. We are adjusting our PT to $97/share from $95/share to reflect the deal price and moving to the sidelines with an MP rating. The deal is expected to close 1Q26."

For an analyst ratings summary and ratings history on Merus N.V. click here. For more ratings news on Merus N.V. click here.

Shares of Merus N.V. closed at $94.29 yesterday.

You May Also Be Interested In

• BofA Securities Downgrades PVH Corp (PVH) to Underperform
• Guggenheim Starts Oklo (OKLO) at Neutral
• BTIG Downgrades Apollo Commercial Real Estate Finance (ARI) to Neutral